Is Your ‘Magic Cream’ Secretly a Steroid?

Topical corticosteroids are one of the most widely prescribed classes of topical drug, and they give rapid relief in almost every inflammatory dermatosis (Pal et al., 2018). On the face, the same speed of relief allows misuse to continue for months without medical review. This page accompanies a two-minute film for patients and sets out the evidence behind each statement in it, so that a clinician who shows the film to a patient knows where each point comes from.

How facial use begins

Patients rarely begin facial steroid use on a dermatologist's advice. In a study of 200 patients who had used topical corticosteroids on the face for at least a month, pharmacists had advised 34.5% of them, friends and relatives 30.5% and non-dermatology physicians 15%, whereas dermatologists had advised only 9% (Sharma et al., 2017). In the same study, 36% used the cream as a fairness or general-purpose cream, and others used it for acne or for melasma and pigmentation. Melasma and hyperpigmentation were also the main concern of patients aged 30 to 39 years in an eastern Indian series, in which 83.8% of 271 users did not know that topical steroids could have side effects (Pal et al., 2018). The lightening that patients seek is real but temporary, since steroids may reduce melanocyte activity and the hypopigmentation usually reverses after withdrawal (Coondoo et al., 2014).

Four actions on the skin

Topical corticosteroids act on the skin through four principal effects: they suppress inflammation, constrict dermal vessels, depress local immunity and inhibit cell proliferation (Niculet et al., 2020).

The anti-inflammatory effect suppresses erythema and inflammatory lesions at first, although flares follow when the cream is stopped (Coondoo et al., 2014). Vasoconstriction narrows the superficial vessels, which dilate again afterwards; after prolonged use the dilatation persists and becomes conspicuous in thinned skin. One proposed mechanism is that chronic use inhibits endothelial nitric oxide, which accumulates and is released on withdrawal to produce erythema, itching and burning. However, the same review describes the evidence for this role as inconclusive (Maskey et al., 2025).

Local immunosuppression impairs the defence against dermatophytes, so that a fungal infection can persist or extend while the rash appears to improve, which is the picture of tinea incognito (Coondoo et al., 2014). Steroid acne presents as monomorphic inflammatory papules and pustules with few or no comedones (Coondoo et al., 2014). It is thought to arise when the steroid degrades the follicular epithelium and the follicular contents spill into the dermis (Maskey et al., 2025). Corticosteroids also inhibit fibroblast proliferation and collagen synthesis, so the dermis thins (Niculet et al., 2020). The small vessels then lose their dermal support, and telangiectasia becomes visible, particularly on the face.

Dependence

With repeated use the skin becomes less responsive, a phenomenon called tachyphylaxis, and patients move to more potent preparations that carry more severe adverse effects (Coondoo et al., 2014). Patients who develop acne, rosacea-like erythema or telangiectasia often continue the cream because they fear a flare on withdrawal. After long-term use, attempted withdrawal can produce a burning, red and scaly face, termed topical steroid dependent face, and the condition can become worse than it was before the cream was first applied (Maskey et al., 2025).

Reading the label

The stems of the WHO International Nonproprietary Names allow a patient to recognise a steroid from the label (World Health Organization, 2018/stembook-2018.pdf)). Names ending in -sone (betamethasone, mometasone, clobetasone, fluticasone), -olone (triamcinolone, fluocinolone) and -onide (fluocinonide, desonide) belong to corticosteroids, and "cort" in a name, as in hydrocortisone, marks one as well. Clobetasol belongs to the -betasol group and is classed among the potent and very potent preparations (Pal et al., 2018). Steroid creams are often combined with an antibiotic, an antifungal, salicylic acid or a retinoid (Coondoo, 2014), so a combination product can still contain a steroid.

Withdrawal

Withdrawal plans usually combine supportive care for physical and psychological symptoms with gradual tapering of the steroid before it is stopped completely (Maskey et al., 2025). Atrophy can recover after the steroid is stopped, although recovery may take months (Coondoo et al., 2014). The film therefore directs patients to a dermatologist for a supervised taper.